Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Immune-Mediated CNS Diseases: a Review

  • 118 Accesses

Abstract

Purpose of Review

This review of central nervous system (CNS) immune-mediated disorders serves as an overview of multiple neuroinflammatory conditions. Organized by CNS site, it gives the reader up to date information on clinical presentation, diagnostic pitfalls, and treatment considerations for the acute phase of these disorders. Special attention is paid to some of the more rare CNS neuroinflammatory disorders, given the treatment and rehabilitation challenges that they present.

Recent Findings

In-depth discussion about conditions that can mimic idiopathic transverse myelitis is emphasized during this review. Also, opsoclonus-myoclonus syndrome is included as a discussion point in this review with the most recent literature cited. A general overview of the most current approaches and considerations for multiple sclerosis, neuromyelitis optica, and autoimmune encephalitis is discussed.

Summary

This review serves as a brief overview of neuroinflammatory conditions most relevant to neurologists and rehabilitation providers who see and manage these patients.

This is a preview of subscription content, log in to check access.

References

Papers of particular interest, published recently have been highlighted as: • Of importance

  1. 1.

    Krishnan C, Kaplin AI, Pardo CA, Kerr DA, Keswani SC. Demyelinating disorders: update on transverse myelitis. Curr Neurol Neurosci Rep. 2006;6(3):236–43.

  2. 2.

    Krishnan C, Kaplin AI, Deshpande DM, Pardo CA, Kerr DA. Transverse myelitis: pathogenesis, diagnosis and treatment. Front Biosci. 2004;9:1483–99.

  3. 3.

    Harzheim M, Schlegel U, Urbach H, Klockgether T, Schmidt S. Discriminatory features of acute transverse myelitis: a retrospective analysis of 45 patients. J Neurol Sci. 2004;217(2):217–23.

  4. 4.

    Scott TF. Nosology of idiopathic transverse myelitis syndromes. Acta Neurol Scand. 2007;115(6):371–6.

  5. 5.

    Kuo SC, Cho WH, Shih HI, Tu YF. Idiopathic acute transverse myelitis in children: a retrospective series. Neuropediatrics. 2015;46(5):307–12.

  6. 6.

    • Huh Y, Park EJ, Jung JW, Oh S, Choi SC. Clinical insights for early detection of acute transverse myelitis in the emergency department. Clin Exp Emerg Med. 2015;2(1):44–50. This citation was flagged due to it being a larger case series (N = 46) and is a more recent study and highlights the potential for misdiagnosis with a myelitis event.

  7. 7.

    • Greenberg BM, Frohman EM. Immune-mediated myelopathies. Continuum (Minneap Minn). 2015;21(1 Spinal Cord Disorders):121–31. This citation was flagged due to it being a newer comprehensive review of myelopathies and the importance of diagnostic category and aggressive treatment where appropriate.

  8. 8.

    • Goh C, Desmond PM, Phal PM. MRI in transverse myelitis. J Magn Reson Imaging. 2014;40(6):1267–79. This citation was flagged due to it highlighting the importance of location of lesions within the spinal cord with a three-dimensional approach in a diagnosis of myelitis and considerations of how location of a lesion within the spinal cord has clear diagnostic implications.

  9. 9.

    Hiraga A, Sakakibara R, Mori M, Yamanaka Y, Ito S, Hattori T. Urinary retention can be the sole initial manifestation of acute myelitis. J Neurol Sci. 2006;251(1–2):110–2.

  10. 10.

    Hammond ER, Kerr DA. Priapism in infantile transverse myelitis. Arch Neurol. 2009 Jul;66(7):894–7.

  11. 11.

    Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59(4):499–505. Review

  12. 12.

    West TW, Hess C, Cree BA. Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies. Semin Neurol. 2012 Apr;32(2):97–113.

  13. 13.

    Nardone R, Versace V, Brigo F, Tezzon F, Zuccoli G, Pikija S, et al. Herpes simplex virus type 2 myelitis: case report and review of the literature. Front Neurol. 2017;8:199.

  14. 14.

    Figueroa D, Isache C, Sands M, Guzman N. An unusual case of acute transverse myelitis caused by HSV-1 infection. IDCases. 2016;5:29–31.

  15. 15.

    Sendi P, Hirzel C, Bloch A, Fischer U, Jeannet N, Berlinger L, et al. Bartonella-associated transverse myelitis. Emerg Infect Dis. 2017;23(4):712–3.

  16. 16.

    Baylor P, Garoufi A, Karpathios T, Lutz J, Mogelof J, Moseley D. Transverse myelitis in 2 patients with Bartonella henselae infection (cat scratch disease). Clin Infect Dis. 2007;45(4):e42–5.

  17. 17.

    • Absoud M, Greenberg BM, Lim M, Lotze T, Thomas T, Deiva K. Pediatric transverse myelitis. Neurology. 2016;87(9 Suppl 2):S46–52. This citation was flagged due to it being one of the more recent comprehensive reviews of myelitis in children.

  18. 18.

    • Dixit P, Garg RK, Malhotra HS, Jain A, Verma R, Sharma PK, et al. Cytokines and matrix metalloproteinases in the cerebrospinal fluid of patients with acute transverse myelitis: an outcome analysis. Inflamm Res. 2016;65(2):125–32. This citation was flagged due to it being one of the few studies that looked at CSF cytokines in patients with myelitis with a control group.

  19. 19.

    Kaplin AI, Deshpande DM, Scott E, Krishnan C, Carmen JS, Shats I, et al. IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest. 2005;115(10):2731–41.

  20. 20.

    Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler. 2010;16(12):1443–52.

  21. 21.

    • El Mekabaty A, Pardo CA, Gailloud P. The yield of initial conventional MRI in 115 cases of angiographically confirmed spinal vascular malformations. J Neurol. 2017;264(4):733–9 This citation was flagged due to it highlighting the low potential yield of MRI with respect to the diagnosis of vascular myelopathies.

  22. 22.

    • Chen J, Gailloud P. Safety of spinal angiography: complication rate analysis in 302 diagnostic angiograms. Neurology. 2011;77(13):1235–40. This citation was flagged to highlight the importance of spinal catheter angiography in diagnosis of vascular myelopathies and also notes a significant rate of misdiagnosis of transverse myelitis that were actually vascular in origin.

  23. 23.

    • Rengarajan B, Venkateswaran S, McMillan HJ. Acute asymmetrical spinal infarct secondary to fibrocartilaginous embolism. Childs Nerv Syst. 2015;31(3):487–91 This citation was flagged (N = 2) as one of the few newer studies noting that fibrocartilaginous embolus is a known mimicker of idiopathic transverse myelitis and it needs to be considered in any patient with an acute myelopathy.

  24. 24.

    • Koch MJ, Stapleton CJ, Agarwalla PK, Torok C, Shin JH, Coumans JV, et al. Open and endovascular treatment of spinal dural arteriovenous fistulas: a 10-year experience. J Neurosurg Spine. 2017;26(4):519–23. This citation was flagged due to it highlighting the importance of consideration of the fact that certain vascular myelopathies are potentially treatable as with dural AV fistulas in this case series (N = 47).

  25. 25.

    • Yoder JA, Lloyd M, Zabrocki L, Auten J. Pediatric acute flaccid paralysis: enterovirus D68-associated anterior myelitis. J Emerg Med. 2017. This case report was flagged to highlight the perspective of Emergency room physicians with respect to a potential myelitis case and to note that cases of acute flaccid myelitis are still occurring outside of the initial outbreak in 2014.

  26. 26.

    • Esposito S, Chidini G, Cinnante C, Napolitano L, Giannini A, Terranova L, et al. Acute flaccid myelitis associated with enterovirus-D68 infection in an otherwise healthy child. Virol J. 2017;14(1):4. This case report was flagged to note the suspected viral link with acute flaccid myelitis.

  27. 27.

    • Messacar K, Schreiner TL, Van Haren K, Yang M, Glaser CA, Tyler KL, et al. Acute flaccid myelitis: a clinical review of US cases 2012–2015. Ann Neurol. 2016;80(3):326–38. This study was flagged as the most comprehensive review of the most recent U.S. data on acute flaccid myelitis.

  28. 28.

    Kalita J, Misra UK, Mandal SK. Prognostic predictors of acute transverse myelitis. Acta Neurol Scand. 1998;98(1):60–3.

  29. 29.

    Misra UK, Kalita J. Can electromyography predict the prognosis of transverse myelitis? J Neurol. 1998;245(11):741–4.

  30. 30.

    Ravaglia S, Moglia A, Bogdanov EI. Presyrinx in children with Chiari malformations. Neurology. 2009;72(22):1966–7.

  31. 31.

    • Vadivelu S, Vadivelu S, Mealy M, Patel S, Kosnik-Infinger L, Becker D. Chiari I malformation in children with transverse myelitis. Dev Neurorehabil. 2017;24:1–6. This study was flagged due to it being one of the newest articles to demonstrate a concern for a link between Chiari malformations and the diagnosis of idiopathic transverse myelitis.

  32. 32.

    Greenberg BM, Thomas KP, Krishnan C, Kaplin AI, Calabresi PA, Kerr DA. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology. 2007;68(19):1614–7.

  33. 33.

    Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG, Therapeutics and Technology Assessment Subcommittee of American Academy of Neurology. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;77(24):2128–34.

  34. 34.

    • Beh SC, Kildebeck E, Narayan R, Desena A, Schell D, Rowe ES, et al. High-dose methotrexate with leucovorin rescue: for monumentally severe CNS inflammatory syndromes. J Neurol Sci. 2017;372:187–95. This citation was flagged due to it highlighting the importance of high-dose IV methotrexate as a therapeutic option for severe CNS inflammatory diseases (N =10).

  35. 35.

    Chiganer EH, Hryb JP, Carnero Contentti E. Myelitis and lupus: clinical manifestations, diagnosis and treatment. Review. Reumatol Clin. 2016.

  36. 36.

    Greenberg BM, Graves D, Remington G, Hardeman P, Mann M, Karandikar N, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler. 2012;18(7):1022–6.

  37. 37.

    • Jones ML, Evans N, Tefertiller C, Backus D, Sweatman M, Tansey K, et al. Activity-based therapy for recovery of walking in individuals with chronic spinal cord injury: results from a randomized clinical trial. Arch Phys Med Rehabil. 2014;95(12):2239–46. This study was flagged as a newer clinical trial that supports the importance of activity-based rehabilitation for patients with spinal cord injuries, even outside of the acute phase.

  38. 38.

    Sadowsky CL, Hammond ER, Strohl AB, Commean PK, Eby SA, Damiano DL, et al. Lower extremity functional electrical stimulation cycling promotes physical and functional recovery in chronic spinal cord injury. J Spinal Cord Med. 2013;36(6):623–31.

  39. 39.

    Dorsi MJ, Belzberg AJ. Nerve transfers for restoration of upper extremity motor function in a child with upper extremity motor deficits due to transverse myelitis: case report. Microsurgery. 2012;32(1):64–7.

  40. 40.

    Hattori Y, Doi K, Baliarsing AS. A part of the ulnar nerve as an alternative donor nerve for functioning free muscle transfer: a case report. J Hand Surg Am. 2002;27(1):150–3.

  41. 41.

    • Marignier R, Cobo Calvo A, Vukusic S. Neuromyelitis optica and neuromyelitis optica spectrum disorders. Curr Opin Neurol. 2017;30(3):208–15. This citation was flagged due to it being a newer comprehensive review of NMO-SD with the new criteria and recognition of the anti-MOG phenotype considerations.

  42. 42.

    Tenembaum S, Chitnis T, Nakashima I, Collongues N, McKeon A, Levy M, et al. Neuromyelitis optica spectrum disorders in children and adolescents. Neurology. 2016;87(9 Suppl 2):S59–66.

  43. 43.

    • Kitley J, Palace J. Therapeutic options in neuromyelitis optica spectrum disorders. Expert Rev Neurother. 2016;16(3):319–29. This citation was flagged due to it being a newer and comprehensive review of best available options for long-term NMO disease management.

  44. 44.

    English C, Aloi JJ. New FDA-approved disease-modifying therapies for multiple sclerosis. Clin Ther. 2015;37(4):691–715.

  45. 45.

    Menge T, Dubey D, Warnke C, Hartung HP, Stüve O. Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother. 2016;16(10):1131–9.

  46. 46.

    Newsome SD, Aliotta PJ, Bainbridge J, Bennett SE, Cutter G, Fenton K, et al. A framework of care in multiple sclerosis, part 2: symptomatic care and beyond. Int J MS Care. 2017;19(1):42–56.

  47. 47.

    • Radwan W, Lucke-Wold B, Robadi IA, Gyure K, Roberts T, Bhatia S. Neurosarcoidosis: unusual presentations and considerations for diagnosis and management. Postgrad Med J. 2016;5. This case series (N= 3) was flagged due to a good demonstration of the heterogeneity of neurosarcoidosis presentation.

  48. 48.

    • Ibitoye RT, Wilkins A, Scolding NJ. Neurosarcoidosis: a clinical approach to diagnosis and management. J Neurol. 2017;264(5):1023–8. This study was flagged due to it being a newer comprehensive review of the diagnostic approach and pitfalls and the options for management for neurosarcoidosis.

  49. 49.

    Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol. 2016;16(1):220.

  50. 50.

    Costallat BL, Ferreira DM, Costallat LT, Appenzeller S. Myelopathy in systemic lupus erythematosus: clinical, laboratory, radiological and progression findings in a cohort of 1,193 patients. Rev Bras Reumatol Engl Ed. 2016;56(3):240–51.

  51. 51.

    Carvajal Alegria G, Guellec D, Mariette X, Gottenberg JE, Dernis E, Dubost JJ, et al. Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS cohort. RMD Open. 2016;2(1)

  52. 52.

    Man BL, Mok CC, Fu YP. Neuro-ophthalmologic manifestations of systemic lupus erythematosus: a systematic review. Int J Rheum Dis. 2014;17(5):494–501.

  53. 53.

    Bak E, Yang HK, Hwang JM. Optic neuropathy associated with primary Sjögren's syndrome: a case series. Optom Vis Sci. 2017;94(4):519–26.

  54. 54.

    Garrett G, Ambrose N, Davids Z, Bindman D. Course of neuropsychiatric symptoms during flares of systemic lupus erythematosus (SLE). Case Rep Psychiatry. 2017;2017:2890436. doi:10.1155/2017/2890436.

  55. 55.

    • Meena JP, Seth R, Chakrabarty B, Gulati S, Agrawala S, Naranje P. Neuroblastoma presenting as opsoclonus-myoclonus: a series of six cases and review of literature. J Pediatr Neurosci. 2016;11(4):373–7. This study was flagged as a newer study of Opsoclonus-myoclonus patients (N=6) and demonstrated a newer finding of a low relapse rate with patients treated appropriately in the acute phase

  56. 56.

    • Blaes F, Dharmalingam B. Childhood opsoclonus-myoclonus syndrome: diagnosis and treatment. Expert Rev Neurother. 2016;16(6):641–8. This study was flagged as a more recent thorough review of diagnostic approach and management options for opsoclonus-myoclonus.

  57. 57.

    • Armangué T, Sabater L, Torres-Vega E, Martínez-Hernández E, Ariño H, Petit-Pedrol M, et al. Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol. 2016;73(4):417–24. This study was cited as one of the largest studies (N =114) of adults with opsoclonus-myoclonus syndrome.

  58. 58.

    Hasegawa S, Matsushige T, Kajimoto M, Inoue H, Momonaka H, Japanese Society for Pediatric Immune-Mediated Brain Diseases, et al. A nationwide survey of opsoclonus-myoclonus syndrome in Japanese children. Brain Dev. 2015;37(7):656–60.

  59. 59.

    • Anand G, Bridge H, Rackstraw P, Chekroud AM, Yong J, Stagg CJ, et al. Cerebellar and cortical abnormalities in paediatric opsoclonus-myoclonus syndrome. Dev Med Child Neurol. 2015;57(3):265–72. This study was cited as one of the few studies that demonstrates a clear imaging abnormality in patients with a history of opsoclonus-myoclonus syndrome as compared to a control group (N = 9).

  60. 60.

    Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Verhulst SJ. CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity. Mov Disord. 2004;19(7):770–7.

  61. 61.

    Nosadini M, Mohammad SS, Suppiej A, Sartori S, Dale RC, IVIG in neurology study group. Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome. Dev Med Child Neurol. 2016;58(11):1180–92.

  62. 62.

    • Mitchell WG, Wooten AA, O'Neil SH, Rodriguez JG, Cruz RE, Wittern R. Effect of increased immunosuppression on developmental outcome of opsoclonus myoclonus syndrome (OMS). J Child Neurol. 2015;30(8):976–82. This citation was flagged to demonstrate that more aggressive treatment for opsoclonus-myoclonus syndrome earlier in the disease course may be associated with better outcomes.

  63. 63.

    Cooper CJ, Said S. West nile virus encephalitis induced opsoclonus-myoclonus syndrome. Neurol Int. 2014;6(2):5359.

  64. 64.

    Karaca S, Kozanoğlu İ, Karakurum Göksel B, Karataş M, Tan M, Yerdelen VD, et al. Therapeutic plasma exchange in neurologic diseases: an experience with 91 patients in seven years. Noro Psikiyatr Ars. 2014;51(1):63–8.

  65. 65.

    • Toyoshima D, Morisada N, Takami Y, Kidokoro H, Nishiyama M, Nakagawa T, et al. Rituximab treatment for relapsed opsoclonus-myoclonus syndrome. Brain Dev. 2016;38(3):346–9. This study was cited highlighting the importance of consideration of rituximab for opsoclonus-myoclonus syndrome.

  66. 66.

    Gadian J, Kirk E, Holliday K, Lim M, Absoud M. Systematic review of immunoglobulin use in paediatric neurological and neurodevelopmental disorders. Dev Med Child Neurol. 2017;59(2):136–44.

  67. 67.

    Mesraoua B, Abbas M, D'Souza A, Miyares FR, Hashem M, Osman Y, et al. Adult opsoclonus-myoclonus syndrome following mycoplasma pneumoniae infection with dramatic response to plasmapheresis. Acta Neurol Belg. 2011;111(2):136–8.

  68. 68.

    Pranzatelli MR, Tate ED, Dukart WS, Flint MJ, Hoffman MT, Oksa AE. Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone. J Pediatr. 2005;147(3):372–8.

  69. 69.

    De Grandis E, Parodi S, Conte M, Angelini P, Battaglia F, Gandolfo C, et al. Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome. Neuropediatrics. 2009;40(3):103–11.

  70. 70.

    Catsman-Berrevoets CE, Aarsen FK, van Hemsbergen ML, van Noesel MM, Hakvoort-Cammel FG, van den Heuvel-Eibrink MM. Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up. Pediatr Blood Cancer. 2009;53(6):1048–53.

  71. 71.

    • Pranzatelli MR, Tate ED. Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome. Brain Dev. 2016;38(5):439–48. This citation was flagged as a comprehensive review of the theory of opsoclonusmyoclonus syndrome as a relapsing and progressive neuroimmunologic disease.

  72. 72.

    Pranzatelli MR, Tate ED, Travelstead AL, Baumgardner CA, Gowda NV, Halthore SN, et al. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil. J Child Neurol. 2009;24(3):316–22.

  73. 73.

    Pike M. Opsoclonus-myoclonus syndrome. Handb Clin Neurol. 2013;112:1209–11.

  74. 74.

    Tate ED, Pranzatelli MR, Verhulst SJ, Markwell SJ, Franz DN, Graf WD, et al. Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome. J Child Neurol. 2012;27(7):875–84.

  75. 75.

    Desai J, Mitchell WG. Acute cerebellar ataxia, acute cerebellitis, and opsoclonus-myoclonus syndrome. J Child Neurol. 2012;27(11):1482–8.

  76. 76.

    Bultmann U, Pierscianek D, Gizewski ER, Schoch B, Fritsche N, Timmann D, et al. Functional recovery and rehabilitation of postural impairment and gait ataxia in patients with acute cerebellar stroke. Gait Posture. 2014;39(1):563–9.

  77. 77.

    • Garg P, Rajasekaran M, Pandey S, Gurusamy G, Balalakshmoji D, Rathinasamy R. Magnetic resonance imaging brain findings in a case of aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, presenting with intractable vomiting and hiccups. J Neurosci Rural Pract. 2017;8(1):135–8. This citation was flagged as an excellent example of the imaging findings that correlate with the vomiting and hiccupping syndrome in NMO patients.

  78. 78.

    Popescu BF, Lennon VA, Parisi JE, Howe CL, Weigand SD, Cabrera-Gómez JA, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology. 2011;76(14):1229–37.

  79. 79.

    Cheng C, Jiang Y, Lu X, Gu F, Kang Z, Dai Y, et al. The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica. BMC Neurol. 2016;16(1):203.

  80. 80.

    Li Y, Jiang B, Chen B, Zhao M, Zhou C, Wang S, et al. Neuromyelitis optica spectrum disorders with multiple brainstem manifestations: a case report. Neurol Sci. 2016;37(2):309–13.

  81. 81.

    • Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, et al. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler. 2014;20(7):843–7. This citation was flagged as one of the larger studies (N = 258) of brainstem manifestations in NMO patients.

  82. 82.

    Nerrant E, Tilikete C. Ocular motor manifestations of multiple sclerosis. J Neuroophthalmol. 2017;13

  83. 83.

    Saleh C, Patsi O, Mataigne F, Beyenburg S. Peripheral (seventh) nerve palsy and multiple sclerosis: a diagnostic dilemma—a case report. Case Rep Neurol. 2016;8(1):27–33.

  84. 84.

    Evlice A, Demir T, Kaleağası C, Özcan F, Demirkıran M. Rare onset symptoms in multiple sclerosis. Acta Clin Belg. 2016;71(3):154–7.

  85. 85.

    Preziosa P, Rocca MA, Mesaros S, Pagani E, Drulovic J, Stosic-Opincal T, et al. Relationship between damage to the cerebellar peduncles and clinical disability in multiple sclerosis. Radiology. 2014;271(3):822–30.

  86. 86.

    Shimizu K, Yuki K, Sadatomo T, Kurisu K. Isolated neurosarcoidosis presenting with multiple cranial nerve palsies. Surg Neurol Int. 2016;7:44.

  87. 87.

    Pohl D, Alper G, Van Haren K, Kornberg AJ, Lucchinetti CF, Tenembaum S, et al. Acute disseminated encephalomyelitis: updates on an inflammatory CNS syndrome. Neurology. 2016;87(9 Suppl 2):S38–45.

  88. 88.

    • Brenton JN, Banwell BL. Therapeutic approach to the management of pediatric demyelinating disease: multiple sclerosis and acute disseminated encephalomyelitis. Neurotherapeutics. 2016;13(1):84–95. This citation was flagged as one of the most comprehensive and thorough reviews of the treatment and management for ADEM.

  89. 89.

    Gable M, Glaser C. Anti-N-methyl-D-aspartate receptor encephalitis appearing as a new-onset psychosis: disease course in children and adolescents within the California Encephalitis Project. Pediatr Neurol. 2017; doi:10.1016/j.pediatrneurol.2017.01.023.

  90. 90.

    • Hallowell S, Tebedge E, Oates M, Hand E. Rituximab for treatment of refractory anti-NMDA receptor encephalitis in a pediatric patient. J Pediatr Pharmacol Ther. 2017;22(2):118–23. This citation was flagged as a newer example of the importance of rituximab for treatment for anti-NMDA receptor antibody encephalitis.

  91. 91.

    • Dale RC, Gorman MP, Lim M. Autoimmune encephalitis in children: clinical phenomenology, therapeutics, and emerging challenges. Curr Opin Neurol. 2017;30(3):334–44. This citation was flagged as one of the newer and more comprehensive reviews of autoimmune encephalitis in children and considerations for management.

  92. 92.

    • Nagappa M, Parayil SB, Mahadevan A, Sinha S, Mathuranath PS, Taly AB. Management of Anti- N-methyl-D-aspartate (NMDA) receptor encephalitis in children. J Child Neurol. 2017;32(5):513–4. This citation was flagged as one of the most recent reviews of management for anti- NMDA receptor antibody encephalitis.

  93. 93.

    • Zhang L, Wu MQ, Hao ZL, Chiang SM, Shuang K, Lin MT, et al. Clinical characteristics, treatments, and outcomes of patients with anti-N-methyl-D-aspartate receptor encephalitis: a systematic review of reported cases. Epilepsy Behav. 2017;68:57–65. This citation was cited as one of the larger series of anti-NMDA receptor antibody encephalitis (N =412) and noted equivalence in efficacy between steroids and IVIg therapy.

  94. 94.

    • McKeon GL, Scott JG, Spooner DM, Ryan AE, Blum S, Gillis D, et al. Cognitive and social functioning deficits after anti-N-methyl-D-aspartate receptor encephalitis: an exploratory case series. J Int Neuropsychol Soc. 2016;22(8):828–38. This citation was flagged exploring the impacts on cognitive function with patients with known anti-NMDA receptor antibody encephalitis.

  95. 95.

    • DeSena AD, Noland DK, Matevosyan K, King K, Phillips L, Qureshi SS, et al. Intravenous methylprednisolone versus therapeutic plasma exchange for treatment of anti-N-methyl-D-aspartate receptor antibody encephalitis: a retrospective review. J Clin Apher. 2015;30(4):212–6. This citation was flagged highlighting a study that demonstrated that plasma exchange may be the most superior first-line therapy for anti-NMDA receptor antibody encephalitis.

  96. 96.

    Beis JM, Renard M. Adult anti-NMDA receptor encephalitis: which physical and rehabilitation medicine program? Case reports and literature review. Ann Phys Rehabil Med. 2016;59S:e153–4.

Download references

Author information

Correspondence to Allen D. DeSena.

Ethics declarations

Conflict of Interest

Allen D. DeSena declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Spinal Cord Injury Rehabilitation

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

DeSena, A.D. Immune-Mediated CNS Diseases: a Review. Curr Phys Med Rehabil Rep 5, 134–142 (2017). https://doi.org/10.1007/s40141-017-0160-y

Download citation

Keywords

  • Immune-mediated CNS diseases
  • Transverse myelitis
  • Multiple sclerosis
  • Neuromyelitis optica
  • Autoimmune encephalitis
  • Acute disseminated encephalomyelitis